SCG101
Phase 2Biologic
SCG101 is one of 68 biologic programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
251 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisPreclinical
Ibrance
PfizerPreclinical
Viread
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
SCG101
SSCG Cell Therapy Pte. Ltd.
Phase 2
Doptelet
AAkarx
Preclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
Vermox
WWim Janssens
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SCG101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- SSCG Cell Therapy Pte. Ltd.